| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Patric J D Delhanty, Dieter Mesotten, Fiona McDougall, Robert C Baxte. Growth hormone rapidly induces resistin gene expression in white adipose tissue of spontaneous dwarf (SDR) rats. Endocrinology. vol 143. issue 6. 2002-06-18. PMID:12021211. |
growth hormone is an important regulator of metabolism; both acromegaly and gh therapy in gh-deficiency are associated with a tendency towards insulin-resistance and loss of adiposity. |
2002-06-18 |
2023-08-12 |
human |
| A Colao, M Dorato, M Pulcrano, F W Rossi, R S Auriemma, G Lombardi, S Lastori. [Somatostatin analogs in the clinical management of pituitary neoplasms]. Minerva endocrinologica. vol 26. issue 3. 2002-05-20. PMID:11753242. |
they were first used to treat acromegaly in the mid 1980s and numerous studies have shown a reduction in gh concentration in over 90% of acromegalic patients. |
2002-05-20 |
2023-08-12 |
Not clear |
| C Parkinson, W M Drake, G Wieringa, A P Yates, G M Besser, P J Traine. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clinical endocrinology. vol 56. issue 3. 2002-05-09. PMID:11940041. |
the purpose of this study was to investigate the effect of serum igf-i normalization on serum lipoproteins and insulin, in patients with acromegaly receiving the gh receptor antagonist pegvisomant. |
2002-05-09 |
2023-08-12 |
Not clear |
| Nienke R Biermasz, Jan W A Smit, Hans van Dulken, Ferdinand Roelfsem. Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly. Clinical endocrinology. vol 56. issue 3. 2002-05-09. PMID:11940042. |
to assess the predictive value of postoperative thyrotrophin releasing hormone (trh)-induced gh responsiveness in relation to (late) postoperative outcome in patients in remission after surgery for acromegaly. |
2002-05-09 |
2023-08-12 |
Not clear |
| Scott G Thomas, Linda J Woodhouse, Sonia M Pagura, Shereen Ezza. Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess. Clinical endocrinology. vol 56. issue 3. 2002-05-09. PMID:11940047. |
fatigue is a prominent symptom among patients with gh excess and acromegaly. |
2002-05-09 |
2023-08-12 |
Not clear |
| H J Kim, S H Kwon, S W Kim, D J Park, C S Shin, K S Park, S Y Kim, B Y Cho, H K Le. Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults. Hormone research. vol 56. issue 3-4. 2002-04-30. PMID:11847474. |
to investigate the diagnostic value of serum insulin-like growth factor-i (igf-i) and insulin-like growth factor-binding protein-3 (igfbp-3) measurements in adult patients with acromegaly and gh deficiency (ghd). |
2002-04-30 |
2023-08-12 |
Not clear |
| P M Stewart, A A Toogood, J W Tomlinso. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Hormone research. vol 56 Suppl 1. 2002-04-29. PMID:11786677. |
patients with acromegaly show a reduction in hepatic-derived metabolites of cortisol/cortisone - levels return to normal when gh concentrations are normalized. |
2002-04-29 |
2023-08-12 |
Not clear |
| Gemma Sesmilo, Wesley P Fairfield, Laurence Katznelson, Karen Pulaski, Pamela U Freda, Vivien Bonert, Eleni Dimaraki, Stavros Stavrou, Mary Lee Vance, Douglas Hayden, Anne Klibansk. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. The Journal of clinical endocrinology and metabolism. vol 87. issue 4. 2002-04-25. PMID:11932303. |
cardiovascular risk factors in acromegaly before and after normalization of serum igf-i levels with the gh antagonist pegvisomant. |
2002-04-25 |
2023-08-12 |
Not clear |
| Gemma Sesmilo, Wesley P Fairfield, Laurence Katznelson, Karen Pulaski, Pamela U Freda, Vivien Bonert, Eleni Dimaraki, Stavros Stavrou, Mary Lee Vance, Douglas Hayden, Anne Klibansk. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. The Journal of clinical endocrinology and metabolism. vol 87. issue 4. 2002-04-25. PMID:11932303. |
gh replacement therapy decreases inflammatory markers of cardiovascular risk, but little is known about these markers in patients with acromegaly. |
2002-04-25 |
2023-08-12 |
Not clear |
| Gemma Sesmilo, Wesley P Fairfield, Laurence Katznelson, Karen Pulaski, Pamela U Freda, Vivien Bonert, Eleni Dimaraki, Stavros Stavrou, Mary Lee Vance, Douglas Hayden, Anne Klibansk. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. The Journal of clinical endocrinology and metabolism. vol 87. issue 4. 2002-04-25. PMID:11932303. |
we investigated the effects of gh receptor blockade on inflammatory and other cardiovascular risk markers in active acromegaly. |
2002-04-25 |
2023-08-12 |
Not clear |
| M Doga, S Bonadonna, A Burattin, A Giustin. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects. Annals of oncology : official journal of the European Society for Medical Oncology. vol 12 Suppl 2. 2002-03-26. PMID:11762359. |
may produce excessive ghrh with subsequent gh hypersecretion and resultant acromegaly. |
2002-03-26 |
2023-08-12 |
human |
| C Parkinson, P J Traine. The place of pegvisomant in the management of acromegaly. Expert opinion on investigational drugs. vol 10. issue 9. 2002-03-15. PMID:11772281. |
conventional treatments for acromegaly include surgery, radiotherapy, dopamine agonists and somatostatin (sms) analogues, which effect disease control by lowering circulating growth hormone (gh). |
2002-03-15 |
2023-08-12 |
Not clear |
| b' S Valdemarsson, S Ljunggren, A Cervin, C Svensson, A Isaksson, C H Nordstr\\xc3\\xb6m, P Siesj\\xc3\\xb. Evaluation of surgery for acromegaly: role of intraoperative growth hormone measurement? Scandinavian journal of clinical and laboratory investigation. vol 61. issue 6. 2002-03-08. PMID:11681536.' |
intraoperative growth hormone (gh ) measurement has earlier been tried to improve surgery for acromegaly. |
2002-03-08 |
2023-08-12 |
Not clear |
| b' S Valdemarsson, S Ljunggren, A Cervin, C Svensson, A Isaksson, C H Nordstr\\xc3\\xb6m, P Siesj\\xc3\\xb. Evaluation of surgery for acromegaly: role of intraoperative growth hormone measurement? Scandinavian journal of clinical and laboratory investigation. vol 61. issue 6. 2002-03-08. PMID:11681536.' |
we calculated gh half-life after adenomectomy and evaluated the possible role of this variable in predicting the final outcome of pituitary surgery in 28 consecutive patients with acromegaly. |
2002-03-08 |
2023-08-12 |
Not clear |
| H S Kooistra, A C Okken. Secretion of prolactin and growth hormone in relation to ovarian activity in the dog. Reproduction in domestic animals = Zuchthygiene. vol 36. issue 3-4. 2002-02-28. PMID:11555356. |
acromegaly is a syndrome of tissue overgrowth and insulin resistance due to excessive growth hormone (gh) production. |
2002-02-28 |
2023-08-12 |
dog |
| H S Kooistra, A C Okken. Secretion of prolactin and growth hormone in relation to ovarian activity in the dog. Reproduction in domestic animals = Zuchthygiene. vol 36. issue 3-4. 2002-02-28. PMID:11555356. |
in contrast with the pulsatile gh secretion seen in healthy dogs, the progestagen-induced plasma gh levels in bitches with acromegaly do not have a pulsatile secretion pattern. |
2002-02-28 |
2023-08-12 |
dog |
| Giovanni Amato, Gherardo Mazziotti, Mario Rotondi, Sergio Iorio, Mauro Doga, Francesca Sorvillo, Giovanni Manganella, Francesco Di Salle, Andrea Giustina, Carlo Carell. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clinical endocrinology. vol 56. issue 1. 2002-02-28. PMID:11849248. |
long-term effects of lanreotide sr and octreotide lar on tumour shrinkage and gh hypersecretion in patients with previously untreated acromegaly. |
2002-02-28 |
2023-08-12 |
Not clear |
| Britt Edén Engström, Pia Burman, F Anders Karlsso. Men with acromegaly need higher doses of octreotide than women. Clinical endocrinology. vol 56. issue 1. 2002-02-28. PMID:11849249. |
to investigate the effect of gender on the response of gh to short-acting octreotide in patients with acromegaly, and on the gh and igf-1 levels during long-term treatment with a slow-release formulation of octreotide. |
2002-02-28 |
2023-08-12 |
Not clear |
| Ulla Feldt-Rasmussen, Roger Abs, Bengt-Ake Bengtsson, Helge Bennmarker, Margareta Bramnert, Elizabeth Hernberg-Ståhl, John P Monson, Björn Westberg, Patrick Wilton, Christian Wüste. Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease. European journal of endocrinology. vol 146. issue 1. 2002-02-25. PMID:11751070. |
to compare baseline characteristics in adult patients with growth hormone (gh) deficiency (ghd) who had previously been treated for cushing's disease or acromegaly with data from patients with ghd of other aetiologies. |
2002-02-25 |
2023-08-12 |
Not clear |
| M Blanco, S Bravo, T García-Caballero, C V Alvarez, R Gallego, A Lambert, G Morel, C Diéguez, A Beira. Localization of growth hormone receptors in rat and human thyroid cells. Cell and tissue research. vol 306. issue 3. 2002-02-06. PMID:11735043. |
it is well established that, in acromegaly, the thyroid gland is larger than normal and that gh increases triiodothyronin concentrations and decreases those of tetraiodothyronin (thyroxine). |
2002-02-06 |
2023-08-12 |
human |